Paclitaxel/sirolimus combination coated drug-eluting stent: In vitro and in vivo drug release studies

Journal of Pharmaceutical and Biomedical Analysis

Volumn 54, Issue 4, 2011, Pages 807-811

  Ma, Xiaodong ^a,b   Oyamada, Shizu ^c   Gao, Fan ^d   Wu, Tim ^a,b   Robich, Michael P ^c   Wu, Hao ^b   Wang, Xingwei ^a   Buchholz, Bryan ^a   McCarthy, Stephen ^a   Gu, Zhiyong ^d   Bianchi, Cesario F ^c   Sellke, Frank W ^c   Laham, Roger ^e  

^a UNIVERSITY OF MASSACHUSETTS LOWELL   (United States)

^b VasoTech Inc   (United States)

^c BROWN UNIVERSITY   (United States)

^d University of Massachusetts   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Amorphous calcium phosphate; Drug eluting stent; Paclitaxel; Poly (d, l lactide co glycolide); Sirolimus

Indexed keywords

AMORPHOUS CALCIUM PHOSPHATE; CALCIUM PHOSPHATE; CYPHER; PACLITAXEL; PHOSPHATE BUFFERED SALINE; POLYGLACTIN; RAPAMYCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTERY INTIMA; ARTICLE; CONTROLLED STUDY; DRUG ELUTING STENT; DRUG RELEASE; DRUG TISSUE LEVEL; IN VITRO STUDY; IN VIVO STUDY; MALE; MATERIAL COATING; NONHUMAN; PH; PILOT STUDY; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; AORTA, ABDOMINAL; CALCIUM PHOSPHATES; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG COMBINATIONS; DRUG-ELUTING STENTS; KINETICS; LACTIC ACID; MALE; MICROSCOPY, ELECTRON, SCANNING; PACLITAXEL; PILOT PROJECTS; POLYGLYCOLIC ACID; RATS; RATS, SPRAGUE-DAWLEY; SIROLIMUS; SOLUBILITY; SURFACE PROPERTIES; TUBULIN MODULATORS;

EID: 78650240100     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.10.027     Document Type: Article

References (23)

1. ®). Vasc. Health Risk Manag. 2008, 4:31-38.
2. Iijima R., Ikari Y., Miyazawa A., Nakajima H., Hara K. Predictors of restenosis after implantation of 2.5mm stents in small coronary arteries. Circ. J. 2004, 68:236-240.
3. Schofer J., Schlüter M., Gershlick A.H., Wijns W., García E., Schampaert E., Breithardt G. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003, 362:1093-1099.
4. Muramatsu T, Tsukahara R., Ho M., Ito Y., Ishimori H., Hirano K., Nakano M., Matsushita M., Leung W. Clinical outcome of stent implantation in small coronary arteries using different type of coronary stents. J. Invasive Cardiol. 2001, 13:634-639.
5. Welt F.G.P., Rogers C. Inflammation and restenosis in the stent era. Arterioscler. Thromb. Vasc. Biol. 2002, 22:1769-1776.
6. Bennett M.R. In-stent stenosis: pathology and implications for the development of drug eluting stents. Heart 2003, 89:218-224.
7. Shah P.K. Inflammation, neointimal hyperplasia, and restenosis: as the leukocytes roll, the arteries thicken. Circulation 2003, 107:2175-2177.
8. Cotran R., Kumar V., Collins T. Robbins pathologic basis of disease 1999, WB Saunders, Philadelphia, pp. 260-328. 6th ed.
9. Leon M.B., Bakhai A. Drug-eluting stents and glycoprotein IIb/IIIa inhibitors: combination therapy for the future. Am. Heart J. 2003, 146:S13-S17.
10. Lin C.E., Garvey D.S., Janero D.R., Letts L.G., Marek P., Richardson S.K., Serebryanik D., Shumway M.J., Tam S.W., Trocha A.M. Combination of paclitaxel and nitric oxide as a novel treatment for the reduction of restenosis. J. Med. Chem. 2004, 47:2276-2282.
11. Nugent M.A., Karnovsky M.J., Edelman E.R. Vascular cell-derived heparan sulfate shows coupled inhibition of basic fibroblast growth factor binding and mitogenesis in vascular smooth muscle cells. Circ. Res. 1993, 73:1051-1060.
12. Lovich M.A., Edelman E.R. Tissue average binding and equilibrium distribution: an example with heparin in arterial tissues. Biophys. J. 1996, 70:1553-1559.
13. Levin A.D., Vukmirovic N., Hwang C.W., Edelman E.R. Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:9463-9467.
14. Mondesire W.H., Jian W., Zhang H., Ensor J., Hung M.-C., Mills G.B., Meric-Bernstam F. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin. Cancer Res. 2004, 10:7031-7042.
15. Klugherz B.D., Llanos G., Lieuallen W., Kopia G.A., Papandreou G., Narayan P., Sasseen B., Adelman S.J., Falotico R., Wilensky R.L. Stent-based delivery of sirolimus for the prevention of restenosis. Coron. Artery. Dis. 2002, 13:183-188.
16. Kothwala D., Raval A., Choubey A., Engineer C., Kotadia H. Paclitaxel drug delivery from cardiovascular stent. Trends Biomater. Artif. Organs 2006, 19:88-92.
17. Pires N.M.M., van der Hoeven B.L., de Vries M.R., Havekes L.M., van Vlijmen B.J., Hennink W.E., Quax P.H.A., Jukema J.W. Local perivascular delivery of anti-restenotic agents from a drug-eluting poly([epsilon]-caprolactone) stent cuff. Biomaterials 2005, 26:5386-5394.
18. Tracy M.A., Ward K.L., Firouzabadian L., Wang Y., Dong N., Qian R., Zhang Y. Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro. Biomaterials 1999, 20:1057-1062.
19. Nakazawa G., Finn A.V., Kolodgie F.D., Virmani R. A review of current devices and a look at new technology: drug-eluting stents. Expert Rev. Med. Devices 2009, 6:33-42.
20. Serruys P.W., Ruygrok P., Neuzner J., Piek J.J., Seth A., Schofer J.J., Richardt G., Wiemer M., Carrie D., Thuesen L. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. EuroIntervention 2006, 2:286-294.
21. Kandzari D.E., Leon M.B. Overview of pharmacology and clinical trials program with the zotarolimus-eluting endeavor stent. J. Interv. Cardiol. 2006, 19:405-413.
22. Virmani R., Guagliumi G., Farb A., Musumeci G., Grieco N., Motta T., Mihalcsik L., Tespili M., Valsecchi O., Kolodgie F.D. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent should we be cautious?. Circulation 2004, 109:701-705.
23. Joner M., Finn A.V., Farb A., Mont E.K., Kolodgie F.D., Ladich E., Kutys R., Skorija K., Gold H.K., Virmani R. Pathology of drug-eluting stents in humans delayed healing and late thrombotic risk. J. Am. Coll. Cardiol. 2006, 48:193-202.